The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact.
Alzheimer's disease
dementia
diversity
high‐income countries
low‐ and middle‐income countries
risk factors
vascular dementia
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
02 May 2024
02 May 2024
Historique:
revised:
27
02
2024
received:
31
10
2023
accepted:
28
02
2024
medline:
2
5
2024
pubmed:
2
5
2024
entrez:
2
5
2024
Statut:
aheadofprint
Résumé
Two of every three persons living with dementia reside in low- and middle-income countries (LMICs). The projected increase in global dementia rates is expected to affect LMICs disproportionately. However, the majority of global dementia care costs occur in high-income countries (HICs), with dementia research predominantly focusing on HICs. This imbalance necessitates LMIC-focused research to ensure that characterization of dementia accurately reflects the involvement and specificities of diverse populations. Development of effective preventive, diagnostic, and therapeutic approaches for dementia in LMICs requires targeted, personalized, and harmonized efforts. Our article represents timely discussions at the 2022 Symposium on Dementia and Brain Aging in LMICs that identified the foremost opportunities to advance dementia research, differential diagnosis, use of neuropsychometric tools, awareness, and treatment options. We highlight key topics discussed at the meeting and provide future recommendations to foster a more equitable landscape for dementia prevention, diagnosis, care, policy, and management in LMICs. HIGHLIGHTS: Two-thirds of persons with dementia live in LMICs, yet research and costs are skewed toward HICs. LMICs expect dementia prevalence to more than double, accompanied by socioeconomic disparities. The 2022 Symposium on Dementia in LMICs addressed advances in research, diagnosis, prevention, and policy. The Nairobi Declaration urges global action to enhance dementia outcomes in LMICs.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIA NIH HHS
ID : R01 AG057234
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG075775
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG051412
Pays : United States
Organisme : NIA NIH HHS
ID : U19 AG068054
Pays : United States
Organisme : NIA NIH HHS
ID : R56 AG061837
Pays : United States
Organisme : NICHD NIH HHS
ID : P01 HD035897
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Organisme : NINDS NIH HHS
ID : UF1 NS125513
Pays : United States
Organisme : NINDS NIH HHS
ID : UH3 NS100605
Pays : United States
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Nichols E, Steinmetz JD, Vollset SE, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7:e105‐e125. doi:10.1016/S2468‐2667(21)00249‐8
Prince MJ, Acosta D, Castro‐Costa E, Jackson J, Shaji KS. Packages of care for dementia in low‐ and middle‐income countries. PLoS Med. 2009;6:e1000176. doi:10.1371/journal.pmed.1000176
Risk factors related to population diversity and disparity determine healthy aging. Nat Med. 2023;29:2183‐2184. doi:10.1038/s41591‐023‐02531‐0
Ibáñez A, Legaz A, Ruiz‐Adame M. Addressing the gaps between socioeconomic disparities and biological models of dementia. Brain. 2023;146:3561‐3564. doi:10.1093/brain/awad236
Wimo A, Gauthier S, Prince M. World Alzheimer Report 2018: The state of the art of dementia research: New frontiers. Alzheimer's Disease International; 2018.
Mattap SM, Mohan D, McGrattan AM, et al. The economic burden of dementia in low‐ and middle‐income countries (LMICs): a systematic review. BMJ Glob Health. 2022;7:e007409. doi:10.1136/bmjgh‐2021‐007409
World Health Organization. Global status report on the public health response to dementia. World Health Organization; 2021.
Ibáñez A, Pina‐Escudero SD, Possin KL, et al. Dementia caregiving across Latin America and the Caribbean and brain health diplomacy. Lancet Healthy Longev. 2021;2:e222‐e231. doi:10.1016/s2666‐7568(21)00031‐3
Ferri CP, Jacob KS. Dementia in low‐income and middle‐income countries: different realities mandate tailored solutions. PLOS Med. 2017;14:e1002271. doi:10.1371/journal.pmed.1002271
Prince M, Comas‐Herrera A, Knapp M, Guerchet M, Karagiannidou M, World Alzheimer report 2016: improving healthcare for people living with dementia: coverage, quality and costs now and in the future 2016. http://www.alz.co.uk/(accessed July 24, 2023)
Johnston K, Preston R, Strivens E, Qaloewai S, Larkins S. Understandings of dementia in low and middle income countries and amongst indigenous peoples: a systematic review and qualitative meta‐synthesis. Aging Ment Health. 2020;24:1183‐1195. doi:10.1080/13607863.2019.1606891
World Health Organization. Global action plan on the public health response to dementia 2017‐2025. World Health Organization; 2017.
James T, Mukadam N, Sommerlad A, et al. Protection against discrimination in national dementia guideline recommendations: a systematic review. PLOS Med. 2022;19:e1003860. doi:10.1371/journal.pmed.1003860
United Nations, Department of Economic and Social Affairs, Population Division (2020). World Population Ageing 2019 (ST/ESA/SER.A/444). n.d.
Franzen S, Smith JE, van den Berg E, et al. Diversity in Alzheimer's disease drug trials: the importance of eligibility criteria. Alzheimers Dement J Alzheimers Assoc. 2022;18:810‐823. doi:10.1002/alz.12433
Llibre‐Guerra JJ, Heavener A, Brucki SMD, et al. A call for clinical trial globalization in Alzheimer's disease and related dementia. Alzheimers Dement. 2023;19:3210‐3221. doi:10.1002/alz.12995
Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement N Y N. 2018;4:195‐214. doi:10.1016/j.trci.2018.03.009
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement N Y N. 2023;9:e12385. doi:10.1002/trc2.12385
Babulal GM, Quiroz YT, Albensi BC, et al. Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: update and areas of immediate need. Alzheimers Dement J Alzheimers Assoc. 2019;15:292‐312. doi:10.1016/j.jalz.2018.09.009
Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812‐826. doi:10.1016/S1474‐4422(08)70169‐8
Suemoto CK, Ferretti‐Rebustini REL, Rodriguez RD, et al. Neuropathological diagnoses and clinical correlates in older adults in Brazil: a cross‐sectional study. PLOS Med. 2017;14:e1002267. doi:10.1371/journal.pmed.1002267
Rajabli F, Feliciano BE, Celis K, et al. Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations. PLOS Genet. 2018;14:e1007791. doi:10.1371/journal.pgen.1007791
Naslavsky MS, Suemoto CK, Brito LA, et al. Global and local ancestry modulate APOE association with Alzheimer's neuropathology and cognitive outcomes in an admixed sample. Mol Psychiatry. 2022;27:4800‐4808. doi:10.1038/s41380‐022‐01729‐x
Mok VCT, Pendlebury S, Wong A, et al. Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID‐19 pandemic, now and in the future. Alzheimers Dement J Alzheimers Assoc. 2020;16:1571‐1581. doi:10.1002/alz.12143
de Erausquin GA, Snyder H, Brugha TS, et al. Chronic neuropsychiatric sequelae of SARS‐CoV‐2: protocol and methods from the Alzheimer's Association Global Consortium. Alzheimers Dement N Y N. 2022;8:e12348. doi:10.1002/trc2.12348
Wu Y‐T, Beiser AS, Breteler MMB, et al. The changing prevalence and incidence of dementia over time—current evidence. Nat Rev Neurol. 2017;13:327‐339. doi:10.1038/nrneurol.2017.63
2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19:1598‐1695. doi:10.1002/alz.13016
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396:413‐446. doi:10.1016/S0140‐6736(20)30367‐6
Mukadam N, Sommerlad A, Huntley J, Livingston G. Population attributable fractions for risk factors for dementia in low‐income and middle‐income countries: an analysis using cross‐sectional survey data. Lancet Glob Health. 2019;7:e596‐e603. doi:10.1016/S2214‐109X(19)30074‐9
Suemoto CK, Mukadam N, Brucki SMD, et al. Risk factors for dementia in Brazil: differences by region and race. Alzheimers Dement. 2023;19:1849‐1857. doi:10.1002/alz.12820
Stephan BCM, Pakpahan E, Siervo M, et al. Prediction of dementia risk in low‐income and middle‐income countries (the 10/66 Study): an independent external validation of existing models. Lancet Glob Health. 2020;8:e524‐e535. doi:10.1016/S2214‐109X(20)30062‐0
Hogervorst E, Schröder‐Butterfill E, Handajani YS, Kreager P, Rahardjo TBW. Dementia and dependency vs. proxy indicators of the active ageing index in Indonesia. Int J Environ Res Public Health. 2021;18:8235. doi:10.3390/ijerph18168235
Santamaria‐Garcia H, Sainz‐Ballesteros A, Hernandez H, et al. Factors associated with healthy aging in Latin American populations. Nat Med. 2023;29:2248‐2258. doi:10.1038/s41591‐023‐02495‐1
Blanken AE, Nation DA. Does gender influence the relationship between high blood pressure and dementia? Highlighting areas for further investigation. J Alzheimers Dis. 2020;78:23‐48. doi:10.3233/JAD‐200245
Peters R, Booth A, Rockwood K, Peters J, D'Este C, Anstey KJ. Combining modifiable risk factors and risk of dementia: a systematic review and meta‐analysis. BMJ Open. 2019;9:e022846. doi:10.1136/bmjopen‐2018‐022846
Siervo M, Harrison SL, Jagger C, Robinson L, Stephan BCM. Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta‐analysis. J Alzheimers Dis JAD. 2014;41:151‐161. doi:10.3233/JAD‐132279
Wimo A, Guerchet M, Ali G‐C, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement J Alzheimers Assoc. 2017;13:1‐7. doi:10.1016/j.jalz.2016.07.150
Crivelli L. LatAm‐FINGERS (Latin America): world‐Wide FINGERS network: the first global network of multidomain dementia prevention trials. Alzheimers Dement. 2020;16:e046953. doi:10.1002/alz.046953
World Health Organization. Risk reduction of cognitive decline and dementia: WHO guidelines. World Health Organization; 2019.
Pistollato F, Iglesias RC, Ruiz R, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer's disease: a focus on human studies. Pharmacol Res. 2018;131:32‐43. doi:10.1016/j.phrs.2018.03.012
Wijesinghe P, Wijeweera G, De Silva KRD. Healthy Brain Ageing and Longevity; the Harmony of Natural Products, APOE Polymorphism, and Melatonin. In: Jagota A, ed. Sleep Clocks Aging Longev. Springer International Publishing; 2023:143‐164. doi:10.1007/978‐3‐031‐22468‐3_7
Mahinrad S, Sorond F, Gorelick PB. The role of vascular risk factors in cognitive impairment and dementia and prospects for prevention. Clin Geriatr Med. 2023;39:123‐134. doi:10.1016/j.cger.2022.07.007
Kalaria R, Akinyemi R, Paddick S, Ihara M. Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health. Expert Rev Neurother. 2023. (in press).
Ferreira NV, Lotufo PA, Marchioni DML, et al. Association between adherence to the MIND diet and cognitive performance is affected by income: the ELSA‐Brasil Study. Alzheimer Dis Assoc Disord. 2022;36:133‐139. doi:10.1097/WAD.0000000000000491
Zhuo M, Chen Z, Zhong M‐L, et al. The global disease burden attributable to a diet low in fibre in 204 countries and territories from 1990 to 2019. Public Health Nutr. 2022;26:1‐12. doi:10.1017/S1368980022001987
Pilleron S, Desport J‐C, Jésus P, et al. Diet, alcohol consumption and cognitive disorders in Central Africa: a Study from the EPIDEMCA program. J Nutr Health Aging. 2015;19:657‐667. doi:10.1007/s12603‐015‐0487‐y
Gomes Gonçalves N, Vidal Ferreira N, Khandpur N, et al. Association between consumption of ultraprocessed foods and cognitive decline. JAMA Neurol. 2023;80:142. doi:10.1001/jamaneurol.2022.4397
Sala‐Vila A, Satizabal CL, Tintle N, et al. Red blood cell DHA Is inversely associated with risk of incident Alzheimer's disease and all‐cause dementia: framingham offspring study. Nutrients. 2022;14:2408. doi:10.3390/nu14122408
Satizabal CL, Himali JJ, Beiser AS, et al. Association of red blood cell omega‐3 fatty acids with MRI markers and cognitive function in midlife: the Framingham heart study. Neurology. 2022;99:e2572‐e2582. doi:10.1212/WNL.0000000000201296
de Bruyn J, Wesana J, Bunting SW, Thilsted SH, Cohen PJ. Fish Acquisition and consumption in the African great lakes region through a food environment lens: a scoping review. Nutrients. 2021;13:2408. doi:10.3390/nu13072408
Tan ZS, Spartano NL, Beiser AS, et al. Physical activity, brain volume, and dementia risk: the Framingham study. J Gerontol A Biol Sci Med Sci. 2017;72:789‐795. doi:10.1093/gerona/glw130
Arifin EN, Braun KL, Hogervorst E. Three pillars of active ageing in Indonesia. Asian Popul Stud. 2012;8:207‐230. doi:10.1080/17441730.2012.680334
O'Donovan G, Lee I‐M, Hamer M, et al. The burden of mild cognitive impairment attributable to physical inactivity in Colombia. Eur Rev Aging Phys Act. 2022;19:28. doi:10.1186/s11556‐022‐00307‐y
Walker KA, Power MC, Gottesman RF. Defining the relationship between hypertension, cognitive decline, and dementia: a review. Curr Hypertens Rep. 2017;19:24. doi:10.1007/s11906‐017‐0724‐3
SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, et al, SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321:553‐561. doi:10.1001/jama.2018.21442
Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta‐analysis. Eur Heart J. 2022;43:4980‐4990. doi:10.1093/eurheartj/ehac584
NCD Risk Factor Collaboration. Trends in adult body‐mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population‐based measurement studies with 19·2 million participants. The Lancet. 2016;387:1377‐1396. doi:10.1016/S0140‐6736(16)30054‐X
Schutte AE, Srinivasapura Venkateshmurthy N, Mohan S, Prabhakaran D. Hypertension in low‐ and middle‐income countries. Circ Res. 2021;128:808‐826. doi:10.1161/CIRCRESAHA.120.318729
Geldsetzer P, Manne‐Goehler J, Marcus M‐E, et al. The state of hypertension care in 44 low‐income and middle‐income countries: a cross‐sectional study of nationally representative individual‐level data from 1·1 million adults. The Lancet. 2019;394:652‐662. doi:10.1016/S0140‐6736(19)30955‐9
Owolabi M, Olowoyo P, Mocumbi A, et al. African control of hypertension through innovative epidemiology and a vibrant ecosystem (ACHIEVE): novel strategies for accelerating hypertension control in Africa. J Hum Hypertens. 2023. doi:10.1038/s41371‐023‐00828‐8
Mahinrad S, Sorond FA, Gorelick PB. Hypertension and cognitive dysfunction: a review of mechanisms, life‐course observational studies and clinical trial results. Rev Cardiovasc Med. 2021;22:1429‐1449. doi:10.31083/j.rcm2204148
Salinas J, O'Donnell A, Kojis DJ, et al. Association of social support with brain volume and cognition. JAMA Netw Open. 2021;4:e2121122. doi:10.1001/jamanetworkopen.2021.21122
Sommerlad A, Kivimäki M, Larson EB, et al. Social participation and risk of developing dementia. Nat Aging. 2023;3:532‐545. doi:10.1038/s43587‐023‐00387‐0
Smith L, Shin JI, López Sánchez GF, et al. Social participation and mild cognitive impairment in low‐ and middle‐income countries. Prev Med. 2022;164:107230. doi:10.1016/j.ypmed.2022.107230
Bowen M, Edgar DF, Hancock B, et al. The prevalence of visual impairment in people with dementia (the PrOVIDe study): a cross‐sectional study of people aged 60‐89 years with dementia and qualitative exploration of individual, carer and professional perspectives. NIHR Journals Library. 2016.
Dawes P, Wolski L, Himmelsbach I, Regan J, Leroi I. Interventions for hearing and vision impairment to improve outcomes for people with dementia: a scoping review. Int Psychogeriatr. 2019;31:203‐221. doi:10.1017/S1041610218000728
Maharani A, Dawes P, Nazroo J, Tampubolon G, Pendleton N. SENSE‐Cog WP1 group. Longitudinal relationship between hearing aid use and cognitive function in older Americans. J Am Geriatr Soc. 2018;66:1130‐1136. doi:10.1111/jgs.15363
Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. The Lancet. 2023;402:786‐797. doi:10.1016/S0140‐6736(23)01406‐X
Leroi I, Simkin Z, Hooper E, et al. Impact of an intervention to support hearing and vision in dementia: the SENSE‐Cog Field Trial. Int J Geriatr Psychiatry. 2020;35:348‐357. doi:10.1002/gps.5231
Sheikh S, Tofique S, Zehra N, et al. SENSE‐Cog Asia: a feasibility study of a hearing intervention to improve outcomes in people with dementia. Front Neurol. 2021;12:654143.
Van Der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primer. 2018;4:18003. doi:10.1038/nrdp.2018.3
Wolters FJ, Ikram MA. Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol. 2019;39:1542‐1549. doi:10.1161/ATVBAHA.119.311908
Paddick S‐M, Longdon AR, Kisoli A, et al. Dementia prevalence estimates in sub‐Saharan Africa: comparison of two diagnostic criteria. Glob Health Action. 2013;6:19646. doi:10.3402/gha.v6i0.19646
Paddick S‐M, Longdon A, Kisoli A, et al. The prevalence of dementia subtypes in rural Tanzania. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2014;22:1613‐1622. doi:10.1016/j.jagp.2014.02.004
Lam BYK, Cai Y, Akinyemi R, et al. The global burden of cerebral small vessel disease in low‐ and middle‐income countries: a systematic review and meta‐analysis. Int J Stroke Off J Int Stroke Soc. 2023;18:15‐27. doi:10.1177/17474930221137019
Akinyemi RO, Owolabi MO, Ihara M, et al. Stroke, cerebrovascular diseases and vascular cognitive impairment in Africa. Brain Res Bull. 2019;145:97‐108. doi:10.1016/j.brainresbull.2018.05.018
Arshad F, Mm S, Paplikar A, Rajendran S, Kalkonde Y, Alladi S. Vascular cognitive impairment in India: challenges and opportunities for prevention and treatment. Cereb Circ—Cogn Behav. 2022;3:100034. doi:10.1016/j.cccb.2021.100034
Alladi S, Kaul S, Meena AK, Somayajula S, Umadevi M, Reddy JM. Pattern of vascular dementia in India: study of clinical features, imaging, and vascular mechanisms from a hospital dementia registry. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc. 2006;15:49‐56. doi:10.1016/j.jstrokecerebrovasdis.2004.09.004
Lam BYK, Yiu B, Ampil E, et al. High burden of cerebral white matter lesion in 9 Asian cities. Sci Rep. 2021;11:11587. doi:10.1038/s41598‐021‐90746‐x
Iadecola C, Duering M, Hachinski V, et al. Vascular cognitive impairment and dementia: jACC scientific expert panel. J Am Coll Cardiol. 2019;73:3326‐3344. doi:10.1016/j.jacc.2019.04.034
World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013‐2020. World Health Organization; 2013.
Khatib R, McKee M, Shannon H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high‐income, middle‐income, and low‐income countries: an analysis of the PURE study data. The Lancet. 2016;387:61‐69. doi:10.1016/S0140‐6736(15)00469‐9
Matuja SS, Ngimbwa J, Andrew L, et al. Stroke characteristics and outcomes in urban Tanzania: data from the Prospective Lake Zone Stroke Registry. Int J Stroke Off J Int Stroke Soc. 2023:17474930231219584. doi:10.1177/17474930231219584
Skrobot OA, Black SE, Chen C, et al. Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study. Alzheimers Dement J Alzheimers Assoc. 2018;14:280‐292. doi:10.1016/j.jalz.2017.09.007
Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global Stroke Fact Sheet 2022. Int J Stroke Off J Int Stroke Soc. 2022;17:18‐29. doi:10.1177/17474930211065917
Owolabi M, Akarolo‐Anthony S, Akinyemi R, et al. The burden of stroke in Africa: a glance at the present and a glimpse into the future: review article. Cardiovasc J Afr. 2015;26:S27‐S38. doi:10.5830/CVJA‐2015‐038
Akinyemi RO, Ovbiagele B, Adeniji OA, et al. Stroke in Africa: profile, progress, prospects and priorities. Nat Rev Neurol. 2021;17:634‐656. doi:10.1038/s41582‐021‐00542‐4
Kaul S, Alladi S, Jabeen S, et al. Intracranial atherosclerosis is the most common stroke subtype: ten‐year data from hyderabad stroke registry (India). Ann Indian Acad Neurol. 2018;21:209. doi:10.4103/aian.AIAN_86_18
Pandian JD, Kalkonde Y, Sebastian IA, Felix C, Urimubenshi G, Bosch J. Stroke systems of care in low‐income and middle‐income countries: challenges and opportunities. Lancet Lond Engl. 2020;396:1443‐1451. doi:10.1016/S0140‐6736(20)31374‐X
Jacob MA, Ekker MS, Allach Y, et al. Global differences in risk factors, etiology, and outcome of ischemic stroke in young adults‐a worldwide meta‐analysis: the GOAL Initiative. Neurology. 2022;98:e573‐e588. doi:10.1212/WNL.0000000000013195
Mavrodaris A, Powell J, Thorogood M. Prevalences of dementia and cognitive impairment among older people in sub‐Saharan Africa: a systematic review. Bull World Health Organ. 2013;91:773‐783. doi:10.2471/BLT.13.118422
Akinyemi RO, Allan L, Owolabi MO, et al. Profile and determinants of vascular cognitive impairment in African stroke survivors: the CogFAST Nigeria Study. J Neurol Sci. 2014;346:241‐249. doi:10.1016/j.jns.2014.08.042
Fang C, Lv L, Mao S, Dong H, Liu B. Cognition deficits in Parkinson's disease: mechanisms and treatment. Park Dis. 2020;2020:2076942. doi:10.1155/2020/2076942
Baiano C, Barone P, Trojano L, Santangelo G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: a meta‐analysis. Mov Disord Off J Mov Disord Soc. 2020;35:45‐54. doi:10.1002/mds.27902
Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010;20:633‐639. doi:10.1111/j.1750‐3639.2009.00369.x
Schiess N, Cataldi R, Okun MS, et al. Six action steps to address global disparities in Parkinson disease: a world health organization priority. JAMA Neurol. 2022;79:929‐936. doi:10.1001/jamaneurol.2022.1783
Akinyemi RO, Okubadejo NN, Akinyemi JO, Owolabi MO, Owolabi LF, Ogunniyi A. Cognitive dysfunction in Nigerians with Parkinson's disease. Mov Disord. 2008;23:1378‐1383. doi:10.1002/mds.22087
Ojo OO, Okubadejo NU, Ojini FI, Danesi MA. Frequency of cognitive impairment and depression in Parkinson's disease: a preliminary case‐control study. Niger Med J J Niger Med Assoc. 2012;53:65‐70. doi:10.4103/0300‐1652.103544
Ojo OO, Wahab KW, Bello AH, et al. A cross‐sectional comprehensive assessment of the profile and burden of non‐motor symptoms in relation to motor phenotype in the Nigeria Parkinson disease registry cohort. Mov Disord Clin Pract. 2021;8:1206‐1215. doi:10.1002/mdc3.13346
Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD‐MCI. Mov Disord Off J Mov Disord Soc. 2011;26:1814‐1824. doi:10.1002/mds.23823
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: hIV infection as a chronic disease. Lancet Lond Engl. 2013;382:1525‐1533. doi:10.1016/S0140‐6736(13)61809‐7
Alford K, Daley S, Banerjee S, Vera JH. Quality of life in people living with HIV‐associated neurocognitive disorder: a scoping review study. PLOS ONE. 2021;16:e0251944. doi:10.1371/journal.pone.0251944
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV‐associated neurocognitive disorders. Neurology. 2007;69:1789‐1799. doi:10.1212/01.WNL.0000287431.88658.8b
Wang Y, Liu M, Lu Q, et al. Global prevalence and burden of HIV‐associated neurocognitive disorder: a meta‐analysis. Neurology. 2020;95:e2610‐e2621. doi:10.1212/WNL.0000000000010752
Nweke MC, Okemuo AJ, Uduonu EM, Ugwu PI, Nwachukwu C, Mshunqane N. Meta‐analysis of factors affecting prevalence estimates of HIV‐associated neurocognitive disorder in sub‐Saharan Africa. South Afr J Sci. 2021;117:1‐10. doi:10.17159/sajs.2021/8575
Mwangala PN, Mabrouk A, Wagner R, Newton CRJC, Abubakar AA. Mental health and well‐being of older adults living with HIV in sub‐Saharan Africa: a systematic review. BMJ Open. 2021;11:e052810. doi:10.1136/bmjopen‐2021‐052810
Dreyer AJ, Nightingale S, Heaps‐Woodruff JM, et al. Rates of cognitive impairment in a South African cohort of people with HIV: variation by definitional criteria and lack of association with neuroimaging biomarkers. J Neurovirol. 2021;27:579‐594. doi:10.1007/s13365‐021‐00993‐x
Robbins RN, Joska JA, Thomas KGF, et al. Exploring the utility of the Montreal Cognitive Assessment to detect HIV‐associated neurocognitive disorder: the challenge and need for culturally valid screening tests in South Africa. Clin Neuropsychol. 2013;27:437‐454. doi:10.1080/13854046.2012.759627
Dreyer AJ, Nightingale S, Andersen LS, et al. Cognitive performance in a South African cohort of people with HIV and comorbid major depressive disorder. J Neurovirol. 2022;28:537‐551. doi:10.1007/s13365‐022‐01093‐0
Nightingale S, Cinque P, Joska JA, Price RW, Underwood J, International HIV‐Cognition Working Group. A new approach to cognitive impairment in people with HIV. Lancet HIV. 2022;9:e815‐e817. doi:10.1016/S2352‐3018(22)00267‐3
Nightingale S, Ances B, Cinque P, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19:424‐433. doi:10.1038/s41582‐023‐00813‐2
Gisslén M, Price RW, Nilsson S. The definition of HIV‐associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11:356. doi:10.1186/1471‐2334‐11‐356
Nightingale S, Winston A, Letendre S, et al. Controversies in HIV‐associated neurocognitive disorders. Lancet Neurol. 2014;13:1139‐1151. doi:10.1016/S1474‐4422(14)70137‐1
Klimova B, Kuca K. Speech and language impairments in dementia. J Appl Biomed. 2016;14:97‐103. doi:10.1016/j.jab.2016.02.002
Salehi M, Reisi M, Ghasisin L. Lexical retrieval or semantic knowledge which one causes naming errors in patients with mild and moderate Alzheimer's disease. Dement Geriatr Cogn Disord Extra. 2017;7:419‐429. doi:10.1159/000484137
Beveridge MEL, Bak TH. The languages of aphasia research: bias and diversity. Aphasiology. 2011;25:1451‐1468. doi:10.1080/02687038.2011.624165
Georgiou EE, Prapiadou S, Thomopoulos V, et al. Naming ability assessment in neurocognitive disorders: a clinician's perspective. BMC Psychiatry. 2022;22:837. doi:10.1186/s12888‐022‐04486‐x
Bose A, Dash NS, Ahmed S, et al. Connected speech characteristics of Bengali speakers with Alzheimer's disease: evidence for language‐specific diagnostic markers. Front Aging Neurosci. 2021;13:707628. doi:10.3389/fnagi.2021.707628
Blanken G, Dittmann J, Haas J‐C, Wallesch C‐W. Spontaneous speech in senile dementia and aphasia: implications for a neurolinguistic model of language production. Cognition. 1987;27:247‐274. doi:10.1016/S0010‐0277(87)80011‐2
Kavé G, Levy Y. Morphology in picture descriptions provided by persons with Alzheimer's disease. J Speech Lang Hear Res JSLHR. 2003;46:341‐352.
Ahmed S, Haigh A‐MF, De Jager CA, Garrard P. Connected speech as a marker of disease progression in autopsy‐proven Alzheimer's disease. Brain. 2013;136:3727‐3737. doi:10.1093/brain/awt269
Siriboonpipattana W, Nickels L, Bastiaanse R. An investigation of time reference in production and comprehension in Thai speakers with agrammatic aphasia. Aphasiology. 2021;35:1168‐1189. doi:10.1080/02687038.2020.1781777
Pearce JMS. A note on aphasia in bilingual patients: pitres’ and Ribot's laws. Eur Neurol. 2005;54:127‐131. doi:10.1159/000089083
Ribot T. Diseases of memory: an essay in the positive psychology. D. Appleton and Company; 1882.
Paradis M. Bilingualism and neuropsychiatric disorders. J Neurolinguistics. 2008;21:199‐230. doi:10.1016/j.jneuroling.2007.09.002
Ellajosyula R, Narayanan J, Patterson K. Striking loss of second language in bilingual patients with semantic dementia. J Neurol. 2020;267:551‐560. doi:10.1007/s00415‐019‐09616‐2
Abuom TO, Obler LK, Bastiaanse R. Using Swahili and English to test explanations of agrammatism. Aphasiology. 2011;25:559‐575. doi:10.1080/02687038.2010.538417
Bialystok E, Abutalebi J, Bak TH, Burke DM, Kroll JF. Aging in two languages: implications for public health. Ageing Res Rev. 2016;27:56‐60. doi:10.1016/j.arr.2016.03.003
Ardila A, Rosselli M. Cognitive world: neuropsychology of individual differences. Appl Neuropsychol Adult. 2018;25:29‐37. doi:10.1080/23279095.2016.1232264
Bak TH, Nissan JJ, Allerhand MM, Deary IJ. Does bilingualism influence cognitive aging? Ann Neurol. 2014;75:959‐963. doi:10.1002/ana.24158
Rosselli M, Loewenstein DA, Curiel RE, et al. Effects of bilingualism on verbal and nonverbal memory measures in mild cognitive impairment. J Int Neuropsychol Soc JINS. 2019;25:15‐28. doi:10.1017/S135561771800070X
Costa A, Hernández M, Costa‐Faidella J, Sebastián‐Gallés N. On the bilingual advantage in conflict processing: now you see it, now you don't. Cognition. 2009;113:135‐149. doi:10.1016/j.cognition.2009.08.001
Kroll JF, Bobb SC, Hoshino N. Two languages in mind: bilingualism as a tool to investigate language, cognition, and the brain. Curr Dir Psychol Sci. 2014;23:159‐163. doi:10.1177/0963721414528511
Perani D, Abutalebi J. Bilingualism, dementia, cognitive and neural reserve. Curr Opin Neurol. 2015;28:618‐625. doi:10.1097/WCO.0000000000000267
Abutalebi J, Della Rosa PA, Green DW, et al. Bilingualism tunes the anterior cingulate cortex for conflict monitoring. CEREB Cortex N Y N 1991. 2012;22:2076‐2086. doi:10.1093/cercor/bhr287
Abutalebi J, Canini M, Della Rosa PA, Sheung LP, Green DW, Weekes BS. Bilingualism protects anterior temporal lobe integrity in aging. Neurobiol Aging. 2014;35:2126‐2133. doi:10.1016/j.neurobiolaging.2014.03.010
Klein D, Mok K, Chen J‐K, Watkins KE. Age of language learning shapes brain structure: a cortical thickness study of bilingual and monolingual individuals. Brain Lang. 2014;131:20‐24. doi:10.1016/j.bandl.2013.05.014
Paap KR, Greenberg ZI. There is no coherent evidence for a bilingual advantage in executive processing. Cognit Psychol. 2013;66:232‐258. doi:10.1016/j.cogpsych.2012.12.002
Hilchey MD, Klein RM. Are there bilingual advantages on nonlinguistic interference tasks? Implications for the plasticity of executive control processes. Psychon Bull Rev. 2011;18:625‐658. doi:10.3758/s13423‐011‐0116‐7
Duñabeitia JA, Hernández JA, Antón E, Macizo P, Estévez A, Fuentes LJ, et al. The inhibitory advantage in bilingual children revisited: myth or reality? Exp Psychol. 2014;61:234‐251. doi:10.1027/1618‐3169/a000243
Scearce‐Levie K, Sanchez PE, Lewcock JW. Leveraging preclinical models for the development of Alzheimer disease therapeutics. Nat Rev Drug Discov. 2020;19:447‐462. doi:10.1038/s41573‐020‐0065‐9
Thornton P, Sevalle J, Deery MJ, et al. TREM2 shedding by cleavage at the H157‐S158 bond is accelerated for the Alzheimer's disease‐associated H157Y variant. EMBO Mol Med. 2017;9:1366‐1378. doi:10.15252/emmm.201707673
Vilalta A, Zhou Y, Sevalle J, et al. Wild‐type sTREM2 blocks Aβ aggregation and neurotoxicity, but the Alzheimer's R47H mutant increases Aβ aggregation. J Biol Chem. 2021;296:100631. doi:10.1016/j.jbc.2021.100631
Kunkle BW, Grenier‐Boley B, Sims R, et al. Genetic meta‐analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414‐430. doi:10.1038/s41588‐019‐0358‐2
Acosta‐Uribe J, Aguillón D, Cochran JN, et al. A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. Genome Med. 2022;14:27. doi:10.1186/s13073‐022‐01035‐9
Ibanez A, Yokoyama JS, Possin KL, et al. The multi‐partner consortium to expand dementia research in Latin America (ReDLat): driving multicentric research and implementation science. Front Neurol. 2021;12:631722. doi:10.3389/fneur.2021.631722
Lopera F. Clinical features of early‐onset Alzheimer disease in a large kindred with an E280A presenilin‐1 mutation. JAMA J Am Med Assoc. 1997;277:793‐799. doi:10.1001/jama.277.10.793
Lalli MA, Cox HC, Arcila ML, et al. Origin of the PSEN1 E280A mutation causing early‐onset Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc. 2014;10:S277‐S283. doi:10.1016/j.jalz.2013.09.005. e10.
Sepulveda‐Falla D, Glatzel M, Lopera F. Phenotypic profile of early‐onset familial Alzheimer's disease caused by presenilin‐1 E280A mutation. J Alzheimers Dis JAD. 2012;32:1‐12. doi:10.3233/JAD‐2012‐120907
Aguirre‐Acevedo DC, Lopera F, Henao E, et al. Cognitive decline in a colombian kindred with autosomal dominant Alzheimer disease: a retrospective cohort study. JAMA Neurol. 2016;73:431. doi:10.1001/jamaneurol.2015.4851
Acosta‐Baena N, Sepulveda‐Falla D, Lopera‐Gómez CM, et al. Pre‐dementia clinical stages in presenilin 1 E280A familial early‐onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 2011;10:213‐220. doi:10.1016/S1474‐4422(10)70323‐9
Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid‐β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross‐sectional study. Lancet Neurol. 2012;11:1057‐1065. doi:10.1016/S1474‐4422(12)70227‐2
Quiroz YT, Sperling RA, Norton DJ, et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 2018;75:548‐556. doi:10.1001/jamaneurol.2017.4907
Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer Disease kindred: a cross‐sectional study. JAMA Neurol. 2015;72:316. doi:10.1001/jamaneurol.2014.3314
Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross‐sectional and longitudinal cohort study. Lancet Neurol. 2020;19:513‐521. doi:10.1016/S1474‐4422(20)30137‐X
Littau JL, Velilla L, Hase Y, et al. Evidence of beta amyloid independent small vessel disease in familial Alzheimer's disease. Brain Pathol. 2022;32:e13097. doi:10.1111/bpa.13097
Sepulveda‐Falla D, Chavez‐Gutierrez L, Portelius E, et al. A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Acta Neuropathol (Berl). 2021;141:217‐233. doi:10.1007/s00401‐020‐02249‐0
Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680‐1683. doi:10.1038/s41591‐019‐0611‐3
Sepulveda‐Falla D, Sanchez JS, Almeida MC, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol (Berl). 2022;144:589‐601. doi:10.1007/s00401‐022‐02467‐8
Lopera F, Marino C, Chandrahas AS, et al. Resilience to autosomal dominant Alzheimer's disease in a Reelin‐COLBOS heterozygous man. Nat Med. 2023;29:1243‐1252. doi:10.1038/s41591‐023‐02318‐3
Akinyemi RO, Owolabi MO, Okubadejo N, Ogunniyi A, Kalaria RN. African dementia consortium. the African dementia consortium. Lancet Neurol. 2023;22:28‐29. doi:10.1016/S1474‐4422(22)00475‐6
Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921‐923. doi:10.1126/science.8346443
Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180‐184. doi:10.1038/ng0694‐180
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta‐analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997;278:1349‐1356.
Rajabli F, Beecham GW, Hendrie HC, et al. A locus at 19q13.31 significantly reduces the ApoE ε4 risk for Alzheimer's disease in African Ancestry. PLOS Genet. 2022;18:e1009977. doi:10.1371/journal.pgen.1009977
Naslavsky MS, Scliar MO, Yamamoto GL, et al. Whole‐genome sequencing of 1,171 elderly admixed individuals from Brazil. Nat Commun. 2022;13:1004. doi:10.1038/s41467‐022‐28648‐3
Chen C‐H, Mizuno T, Elston R, et al. A comparative study to screen dementia and APOE genotypes in an ageing East African population. Neurobiol Aging. 2010;31:732‐740. doi:10.1016/j.neurobiolaging.2008.06.014
Wijesinghe P, Shankar SK, Yasha TC, et al. Vascular contributions in Alzheimer's disease‐related neuropathological changes: first autopsy evidence from a South Asian aging population. J Alzheimers Dis. 2016;54:1607‐1618. doi:10.3233/JAD‐160425
Blue EE, Horimoto ARVR, Mukherjee S, Wijsman EM, Thornton TA. Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics. Alzheimers Dement J Alzheimers Assoc. 2019;15:1524‐1532. doi:10.1016/j.jalz.2019.07.016
Griswold AJ, Celis K, Bussies PL, et al. Increased APOE ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds. Alzheimers Dement. 2021;17:1179‐1188. doi:10.1002/alz.12287
Jack CR, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc. 2018;14:535‐562. doi:10.1016/j.jalz.2018.02.018
Kallmyer B, Daven M, Thornhill L, Clifford K, Conant R, Carrillo M. Editorial: impact of Aduhelm approval on care and policy. J Prev Alzheimers Dis. 2021;8:396‐397. doi:10.14283/jpad.2021.42
Gautier S, Webster C, Servaes S, Morais JA, Rosa‐Neto P. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. Alzheimer's Disease International; 2022.
Alzheimer's Disease International. World Alzheimer Report 2019: Attitudes to dementia. Alzheimer's Disease International; 2019.
Bellaj T, Ben Jemaa S, Khelifa M, Ben Djebara M, Gouider R, Le Gall D. The development of the dementia screening battery‐100: instrument presentation, reliability, and construct validity. Dement Geriatr Cogn Disord Extra. 2017;7:215‐229. doi:10.1159/000477437
Parker M, Barlow S, Hoe J, Aitken L. Persistent barriers and facilitators to seeking help for a dementia diagnosis: a systematic review of 30 years of the perspectives of carers and people with dementia. Int Psychogeriatr. 2020:1‐24. doi:10.1017/S1041610219002229
Tsoy E, Kiekhofer RE, Guterman EL, et al. Assessment of Racial/ethnic disparities in timeliness and comprehensiveness of dementia diagnosis in California. JAMA Neurol. 2021;78:657‐665. doi:10.1001/jamaneurol.2021.0399
Parra MA, Baez S, Sedeño L, et al. Dementia in Latin America: paving the way toward a regional action plan. Alzheimers Dement. 2021;17:295‐313. doi:10.1002/alz.12202
for The Latin America and the Caribbean Consortium on Dementia (LAC‐CD), Ibanez A, Parra MA, Butler C, for The Latin America and the Caribbean Consortium on Dementia (LAC‐CD). The Latin America and the Caribbean Consortium on Dementia (LAC‐CD): from networking to research to implementation science. J Alzheimers Dis. 2021;82:S379‐S394. doi:10.3233/JAD‐201384
Ellajosyula R, Narayanan J, Hegde S, et al. Delay in the diagnosis of dementia in urban India: role of dementia subtype and age at onset. Int J Geriatr Psychiatry. 2022;37. doi:10.1002/gps.5843. gps.5843.
Plattner IE, Mbakile‐Mahlanza L, Marobela S, et al. Developing a computerized brief cognitive screening battery for Botswana: a feasibility study. Arch Clin Neuropsychol. 2019;34:682‐689. doi:10.1093/arclin/acy071
Porrselvi A, Shankar V. Status of cognitive testing of adults in India. Ann Indian Acad Neurol. 2017;20:334. doi:10.4103/aian.AIAN_107_17
Ahmed T, Kumar K, Zhang P. A systematic review of the status of neuropsychological research and dementia in South Asia. Discov Psychol. 2023;3:16. doi:10.1007/s44202‐023‐00078‐2
Gugssa SA, Zenebe Y, Seeger S, Comeau D, Derbew M, Cross‐cultural adaptation of AD‐8 into Amharic for operationalizing the detection of cognitive impairment in a primary care setting of Ethiopia. In Review; 2022. doi:10.21203/rs.3.rs‐1820446/v1
Amaral‐Carvalho V, Lima‐Silva TB, Mariano LI, et al. Brazilian Version of Addenbrooke's cognitive examination—revised in the differential diagnosis of Alzheimer's disease and behavioral variant frontotemporal dementia. Arch Clin Neuropsychol. 2022;37:437‐448. doi:10.1093/arclin/acab071
Okada De Oliveira M, Cesar KG, Allen IE, Mioshi E, Nitrini R, Dozzi Brucki SM. Development of the Brazilian Mini‐Addenbrooke's cognitive examination (BR M‐ACE). Alzheimers Dement. 2019;15:P796‐P797. doi:10.1016/j.jalz.2019.06.2876
Allegri RF, Villavicencio AF, Taragano FE, Rymberg S, Mangone CA, Baumann D. Spanish boston naming test norms. Clin Neuropsychol. 1997;11:416‐420. doi:10.1080/13854049708400471
Blanco R, Román F, Iturry M, et al. Cuestionario de detección de deterioro cognitivo AD8‐arg para su uso Atención Primaria de la salud en Argentina. Neurol Argent. 2016;8:231‐236. doi:10.1016/j.neuarg.2016.10.001
Roman F, Iturry M, Rojas G, Barceló E, Buschke H, Allegri RF. Validation of the Argentine version of the Memory Binding Test (MBT) for Early Detection of Mild Cognitive Impairment. Dement Neuropsychol. 2016;10:217‐226. doi:10.1590/S1980‐5764‐2016DN1003008
Maito MA, Santamaría‐García H, Moguilner S, et al. Classification of Alzheimer's disease and frontotemporal dementia using routine clinical and cognitive measures across multicentric underrepresented samples: a cross sectional observational study. Lancet Reg Health—Am. 2023;17:100387. doi:10.1016/j.lana.2022.100387
Moguilner S, Birba A, Fittipaldi S, et al. Multi‐feature computational framework for combined signatures of dementia in underrepresented settings. J Neural Eng. 2022;19:046048. doi:10.1088/1741‐2552/ac87d0
Ben Jemaa S, Marzouki Y, Fredj M, Le Gall D, Bellaj T. The adaptation and validation of an Arabic version of the Cornell scale for depression in dementia (A‐CSDD). J Alzheimers Dis. 2019;67:839‐848. doi:10.3233/JAD‐180448
Ben Jemaa S, Attia Romdhane N, Bahri‐Mrabet A, Jendli A, Le Gall D, Bellaj T. An Arabic version of the cognitive subscale of the Alzheimer's disease assessment scale (ADAS‐Cog): reliability, Validity, and Normative Data. J Alzheimers Dis. 2017;60:11‐21. doi:10.3233/JAD‐170222
Mbakile‐Mahlanza L, Validation of a cognitive assessment battery in the Botswana population 2020. https://iadrp.nia.nih.gov/project/validation‐cognitive‐assessment‐battery‐botswana‐population (accessed July 8, 2023)
Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology. 2000;55:1613‐1620. doi:10.1212/01.wnl.0000434309.85312.19
Meghana R, Jain S, Malo PK, Stezin A, Issac TG. Potential modifications on verbal‐language/orientation‐memory ratio from Addenbrooke's cognitive examination III to predict mild cognitive impairment from healthy controls. J Neurosci Rural Pract. 2023;14:531‐532. doi:10.25259/JNRP_223_2023
Paddick S‐M, Gray WK, McGuire J, Richardson J, Dotchin C, Walker RW. Cognitive screening tools for identification of dementia in illiterate and low‐educated older adults, a systematic review and meta‐analysis. Int Psychogeriatr. 2017;29:897‐929. doi:10.1017/S1041610216001976
Rosselli M, Uribe IV, Ahne E, Shihadeh L. Culture, ethnicity, and level of education in Alzheimer's disease. Neurotherapeutics. 2022;19:26‐54. doi:10.1007/s13311‐022‐01193‐z
Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc. 2022;18:2669‐2686. doi:10.1002/alz.12756
Schlesinger D, Grinberg LT, Alba JG, et al. African ancestry protects against Alzheimer's disease‐related neuropathology. Mol Psychiatry. 2013;18:79‐85. doi:10.1038/mp.2011.136
Chaudhry A, Rizig M. Comparing fluid biomarkers of Alzheimer's disease between African American or Black African and white groups: a systematic review and meta‐analysis. J Neurol Sci. 2021;421:117270. doi:10.1016/j.jns.2020.117270
Simrén J, Ashton NJ, Blennow K, Zetterberg H. Blood neurofilament light in remote settings: alternative protocols to support sample collection in challenging pre‐analytical conditions. Alzheimers Dement Amst Neth. 2021;13:e12145. doi:10.1002/dad2.12145
Gauthier S, Rosa‐Neto P, Morais J, Webster C. World Alzheimer Report 2021: Journey through the diagnosis of dementia. Alzheimer's Disease International; 2021.
Grinberg LT, de Ferretti RE L, Farfel JM, et al. Brain bank of the Brazilian aging brain study group—a milestone reached and more than 1,600 collected brains. Cell Tissue Bank. 2007;8:151‐162. doi:10.1007/s10561‐006‐9022‐z
Akinyemi RO, Salami A, Akinyemi J, et al. Brain banking in low and middle‐income countries: raison D’être for the Ibadan brain ageing, dementia and neurodegeneration (IBADAN) Brain Bank Project. Brain Res Bull. 2019;145:136‐141. doi:10.1016/j.brainresbull.2018.08.014
Akinyemi R, Ojagbemi A, Akinyemi J, et al. Gender differential in inclination to donate brain for research among Nigerians: the IBADAN Brain Bank Project. Cell Tissue Bank. 2019;20:297‐306. doi:10.1007/s10561‐019‐09769‐4
Ogeng'o JA, Cohen DL, Sayi JG, et al. Cerebral amyloid beta protein deposits and other Alzheimer lesions in non‐demented elderly east Africans. Brain Pathol Zurich Switz. 1996;6:101‐107. doi:10.1111/j.1750‐3639.1996.tb00790.x
Akinyemi RO, Jenkins C, Nichols M, et al. Unraveling the ethical, legal, and social implications of neurobiobanking and stroke genomic research in Africa: a Study Protocol of the African Neurobiobank for precision stroke medicine ELSI project. Int J Qual Methods. 2020;19:160940692092319. doi:10.1177/1609406920923194
Singh A, Arulogun O, Akinyemi J, et al. Biological sample donation and informed consent for neurobiobanking: evidence from a community survey in Ghana and Nigeria. PLOS ONE. 2022;17:e0267705. doi:10.1371/journal.pone.0267705
Adigun M, Ojebuyi BR, Akinyemi J, et al. Legal implications of stroke biobanking and genomics research in Sub‐Saharan Africa. J Law Med. 2022;29:579‐598.
Grinberg LT, Nitrini R, Suemoto CK, et al. Prevalence of dementia subtypes in a developing country: a clinicopathological study. Clin Sao Paulo Braz. 2013;68:1140‐1145. doi:10.6061/clinics/2013(08)13
Wijekoon N, Gonawala L, Wijesinghe P, Steinbusch HW, Mohan C, De Silva KRD. A biobank in Sri Lanka that links East and West. Lancet Neurol. 2020;19:972. doi:10.1016/S1474‐4422(20)30405‐1
Wijekoon N, Gonawala L, Ratnayake P, et al. Gene therapy for selected neuromuscular and trinucleotide repeat disorders – An insight to subsume South Asia for multicenter clinical trials. IBRO Neurosci Rep. 2023;14:146‐153. doi:10.1016/j.ibneur.2023.01.009
Agyeman N, Guerchet M, Nyame S, et al. “When someone becomes old then every part of the body too becomes old”: experiences of living with dementia in Kintampo, rural Ghana. Transcult Psychiatry. 2019;56:895‐917. doi:10.1177/1363461519847054
Hurzuk S, Farina N, Pattabiraman M, et al. Understanding, experiences and attitudes of dementia in India: a qualitative study. Dement Lond Engl. 2022;21:2288‐2306. doi:10.1177/14713012221118774
Breuer E, Comas‐Herrera A, Freeman E, et al. Beyond the project: building a strategic theory of change to address dementia care, treatment and support gaps across seven middle‐income countries. Dement Lond Engl. 2022;21:114‐135. doi:10.1177/14713012211029105
Musyimi C, Ndetei D, Muyela LA, Masila J, Mutunga E, Farina N. Integration and evaluation of a community‐level dementia screening program in Kenya (DEM‐SKY): a Protocol. J Alzheimers Dis. 2023;95:1771‐1776. doi:10.3233/JAD‐230107
Govia I, Robinson JN, Amour R, et al. Mapping long‐term care in Jamaica: addressing an ageing population. Sustainability. 2021;13:8101. doi:10.3390/su13148101
Leroi I, Chaudhry N, Daniel A, et al. A roadmap to develop dementia research capacity and capability in Pakistan: a model for low‐ and middle‐income countries. Alzheimers Dement N Y N. 2019;5:939‐952. doi:10.1016/j.trci.2019.11.005
Maestre G, Carrillo M, Kalaria R, et al. The Nairobi Declaration—Reducing the burden of dementia in low‐ and middle‐income countries (LMICs): declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs. Alzheimers Dement. 2023;19:1105‐1108. doi:10.1002/alz.13025